Midnight MarketsV1.0
⚠ Not financial adviceNot financial advice. Independent research, not investment recommendations. The author and website make no representation as to accuracy or completeness. Do your own due diligence before acting on anything you read here. Read the full disclaimer →
The Sequencing & Diagnostics — Illumina, IDEXX & the Lab-Instrument Oligopoly · The GLP-1 & Bio Supply Chain — Peptides, Bioprocessing & Diagnostics

ILMN

Illumina
loading…
History0 bars

~60% of global DNA sequencing instrument placements. SomaLogic acquisition completed Jan 2026.

What they do

Per Mordor Intelligence (2025), Illumina retains roughly 60% of global next-gen sequencing instrument placements (down from ~70–80% in earlier years). Completed SomaLogic acquisition January 30, 2026, adding proteomics integration. Razor/razor-blade business model: sell instruments at modest margin, then sell sequencing reagents (consumables) at very high margin for the instrument's 10-year life.